Early Percutaneous Coronary Intervention, Platelet Inhibition With Eptifibatide, and Clinical Outcomes in Patients With Acute Coronary Syndromes | Zendy

Neal S. Kleiman | Zendy; A. Michael Lincoff | Zendy; Greg C. Flaker | Zendy; Karen S. Pieper | Zendy; Robert G. Wilcox | Zendy; Lisa G. Berdan | Zendy; Todd J. Lorenz | Zendy; Dennis V. Cokkinos | Zendy; Maarten L. Simoons | Zendy; Eric Boersma | Zendy; Eric J. Topol | Zendy; Robert M. Califf | Zendy; Robert A. Harrington | Zendy

Open Access

Early Percutaneous Coronary Intervention, Platelet Inhibition With Eptifibatide, and Clinical Outcomes in Patients With Acute Coronary Syndromes

Author(s) -

Neal S. Kleiman,

A. Michael Lincoff,

Greg C. Flaker,

Karen S. Pieper,

Robert G. Wilcox,

Lisa G. Berdan,

Todd J. Lorenz,

Dennis V. Cokkinos,

Maarten L. Simoons,

Eric Boersma,

Eric J. Topol,

Robert M. Califf,

Robert A. Harrington

Publication year - 2000

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.101.7.751

Subject(s) - eptifibatide , conventional pci , medicine , percutaneous coronary intervention , myocardial infarction , cardiology , acute coronary syndrome , abciximab

Platelet glycoprotein (GP) IIb/IIIa antagonists prevent the composite end point of death or myocardial infarction (MI) in patients with acute coronary syndromes. There is uncertainty about whether this effect is confined to patients who have percutaneous coronary interventions (PCIs) and whether PCIs further prevent death or MI in patients already treated with GP IIb/IIIa antagonists.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research